➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

McKinsey
Medtronic
Boehringer Ingelheim
Harvard Business School
Baxter
Merck

Last Updated: September 30, 2020

DrugPatentWatch Database Preview

Patent: 9,365,510

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

Summary for Patent: 9,365,510
Title:Aziridine bisphenol ethers and related compounds and methods for their use
Abstract: Compounds having a structure of Formula I: ##STR00001## or a pharmaceutically acceptable salt, tautomer or stereoisomer thereof, wherein R, R.sup.1, R.sup.2, R.sup.3, R.sup.4, M.sup.1, M.sup.2, X, L.sup.1, L.sup.2, J.sup.1, J.sup.2, a.sup.1, a.sup.2, b.sup.1 and b.sup.2 are as defined herein, and wherein at least one of M.sup.2 or L.sup.2 is a moiety comprising an aziridine, acrylamide or sulfonate functional group, are provided. Uses of such compounds for treatment of various indications, including prostate cancer as well as methods of treatment involving such compounds are also provided.
Inventor(s): Andersen; Raymond John (Vancouver, CA), Sadar; Marianne Dorothy (Vancouver, CA)
Assignee: British Columbia Cancer Agency Branch (CA) The University of British Columbia (CA)
Application Number:13/863,849
Patent Claims:see list of patent claims

Details for Patent 9,365,510

Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Estimated Patent Expiration Status Orphan Source
Genentech AVASTIN bevacizumab VIAL; INTRAVENOUS 125085 001 2004-02-26   Start Trial British Columbia Cancer Agency Branch (CA) The University of British Columbia (CA) 2039-02-26 RX Orphan search
Genentech AVASTIN bevacizumab VIAL; INTRAVENOUS 125085 002 2004-02-26   Start Trial British Columbia Cancer Agency Branch (CA) The University of British Columbia (CA) 2039-02-26 RX Orphan search
Bristol Myers Squibb YERVOY ipilimumab INJECTABLE; INJECTION 125377 001 2011-03-25   Start Trial British Columbia Cancer Agency Branch (CA) The University of British Columbia (CA) 2039-02-26 RX Orphan search
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Number >Approval Date >Patent No. >Assignee >Estimated Patent Expiration >Status >Orphan >Source

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
Harvard Business School
Mallinckrodt
Johnson and Johnson
McKinsey
Medtronic

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.